Adherence to PEG/ribavirin treatment for chronic hepatitis C: Prevalence, patterns, and predictors of missed doses and nonpersistence

Journal of Viral Hepatitis

Volumn 20, Issue 8, 2013, Pages 536-549

  Evon, D M ^a   Esserman, D A ^a,b   Bonner, J E ^a   Rao, T ^b   Fried, M W ^a   Golin, C E ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b IL   (United States)

Author keywords

compliance; dose; interferon; liver; medication adherence

Indexed keywords

PEGINTERFERON; RIBAVIRIN;

ANTIVIRAL THERAPY; ARTICLE; EMPLOYMENT; EMPLOYMENT STATUS; HEPATITIS C; HUMAN; MARRIAGE; MEDICATION COMPLIANCE; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT PREFERENCE; PRIORITY JOURNAL; SOCIAL SUPPORT; THERAPY EFFECT;

COMPLIANCE; DOSE; INTERFERON; LIVER; MEDICATION ADHERENCE;

DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; MALE; MEDICATION ADHERENCE; RIBAVIRIN; RISK FACTORS; TIME FACTORS;

EID: 84879755957     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12079     Document Type: Article

References (38)

1. McHutchison JG, Manns M, Patel K, et al,. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastro 2002; 123 (4): 1061-1069.
2. Lo Re V III, Amorosa VK, Localio AR, et al,. Adherence to hepatitis C virus therapy and early virologic outcomes. Clin Infect Dis 2009; 48 (2): 186-193.
3. Claxton AJ, Cramer J, Pierce C,. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001; 23 (8): 1296-1310.
4. Grebely J, Matthews GV, Hellard M, et al,. Adherence to treatment for recently acquired hepatitis C virus (HCV) infection among injecting drug users. J Hepatol 2011; 55 (1): 76-85.
5. Cramer JA, Roy A, Burrell A, et al,. Medication compliance and persistence: terminology and definitions. Value Health 2008; 11 (1): 44-47.
6. Urquhart J, Vrijens B,. New findings about patient adherence to prescribed drug dosing regimens: an introduction to pharmionics. Euro J Hosp Pharm Sci 2005; 11 (5): 103-106.
7. Vrijens B, Vincze G, Kristanto P, Urquhart J, Burnier M,. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ 2008; 336 (7653): 1114-1117.
8. Alam I, Stainbrook T, Cecil B, Kistler KD,. Enhanced adherence to HCV therapy with higher dose ribavirin formulation: final analyses from the ADHERE registry. Aliment Pharmacol Ther 2010; 32 (4): 535-542.
9. Cacoub P, Ouzan D, Melin P, et al,. Patient education improves adherence to peg-interferon and ribavirin in chronic genotype 2 or 3 hepatitis C virus infection: a prospective, real-life, observational study. World J Gastroenterol 2008; 14 (40): 6195-6203.
10. Fumaz CR, Munoz-Moreno JA, Ballesteros AL, et al,. Influence of the type of pegylated interferon on the onset of depressive and neuropsychiatric symptoms in HIV-HCV coinfected patients. AIDS Care 2007; 19 (1): 138-145.
11. Weiss JJ, Bhatti L, Dieterich DT, et al,. Hepatitis C patients' self-reported adherence to treatment with pegylated interferon and ribavirin. Aliment Pharmacol Ther 2008; 28 (3): 289-293.
12. Conjeevaram HS, Fried MW, Jeffers LJ, et al,. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 2006; 131 (2): 470-477.
13. Lo Re V III, Teal V, Localio AR, Amorosa VK, Kaplan DE, Gross R,. Relationship between adherence to hepatitis C virus therapy and virologic outcomes: a cohort study. Ann Intern Med 2011; 155 (6): 353-360.
14. Bosworth HB, Oddone EZ, Weinberger M, eds. Patient Treatment Adherence: Concepts, Interventions, and Measurement. Mahwah, New Jersey: Lawrence Erlbaum Associates, Inc., 2006.
15. Weiss JJ, Brau N, Stivala A, Swan T, Fishbein D,. Review article: adherence to medication for chronic hepatitis C-building on the model of human immunodeficiency virus antiretroviral adherence research. Aliment Pharmacol Ther 2009; 30 (1): 14-27.
16. Pherson-Baker S, Jones D, Duran RE, Klimas N, Schneiderman N,. Development and implementation of a medication adherence training instrument for persons living with HIV: the MATI. Behav Modif 2005; 29 (2): 286-317.
17. Radloff LS,. The CES-D Scale: a self-report depression scale for research in the general population. Appl Psychol Measurement 1977; 1 (3): 385-401.
18. Ware JE, Snow KK, Kosinski M, Gandek B,. SF-36 Health Survey Manual and Interpretation Guide. Boston, MA: New England Medical Center, The Health Institute, 1993.
19. Sherbourne CD, Stewart AL,. The MOS social support survey. Soc Sci Med 1991; 32 (6): 705-714.
20. Liu H, Golin CE, Miller LG, et al,. A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med 2001; 134 (10): 968-977.
21. Chesney MA, Ickovics JR, Chambers DB, et al,. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG). AIDS Care 2000; 12 (3): 255-266.
22. Smith SR, Rublein JC, Marcus C, Brock TP, Chesney MA,. A medication self-management program to improve adherence to HIV therapy regimens. Patient Educ Couns 2003; 50 (2): 187-199.
23. Rodis JL, Kibbe P,. Evaluation of medication adherence and quality of life in patients with hepatitis C virus receiving combination therapy. Gastroenterol Nurs 2010; 33 (5): 368-373.
24. Hiramatsu N, Oze T, Yakushijin T, et al,. Ribavirin dose reduction raises relapse rate dose-dependently in genotype 1 patients with hepatitis C responding to pegylated interferon alpha-2b plus ribavirin. J Viral Hepat 2009; 16 (8): 586-594.
25. Antoni MH, Lechner S, Diaz A, et al,. Cognitive behavioral stress management effects on psychosocial and physiological adaptation in women undergoing treatment for breast cancer. Brain Behav Immun 2009; 23 (5): 580-591.
26. Andersen BL, Farrar WB, Golden-Kreutz DM, et al,. Psychological, behavioral, and immune changes after a psychological intervention: a clinical trial. J Clin Oncol 2004; 22 (17): 3570-3580.
27. Brennan RamirezLK, Baker EA, Metzler M,. Promoting Health Equity: A Resource to Help Communities Address Social Determinants of Health. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2008.
28. Evon DM, Verma A, Dougherty KA, et al,. High deferral rates and poorer treatment outcomes for HCV patients with psychiatric and substance use comorbidities. Dig Dis Sci 2007; 52 (11): 3251-3258.
29. Muir AJ, Provenzale D,. A descriptive evaluation of eligibility for therapy among veterans with chronic hepatitis C virus infection. J Clin Gastroenterol 2002; 34 (3): 268-271.
30. Fried MW,. Side effects of therapy of hepatitis C and their management. Hepatology 2002; 36 (5 Suppl 1): S237-S244.
31. Schaefer M, Hinzpeter A, Mohmand A, et al,. Hepatitis C treatment in "difficult-to-treat" psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects. Hepatology 2007; 46 (4): 991-998.
32. Sylvestre DL, Clements BJ,. Adherence to hepatitis C treatment in recovering heroin users maintained on methadone. Eur J Gastroenterol Hepatol 2007; 19 (9): 741-747.
33. Liu H, Miller LG, Golin CE, et al,. Repeated measures analyses of dose timing of antiretroviral medication and its relationship to HIV virologic outcomes. Stat Med 2007; 26 (5): 991-1007.
34. Thompson MA, Mugavero MJ, Amico KR, et al,. Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-Based recommendations from an International Association of Physicians in AIDS care panel. Ann Intern Med 2012; 156 (11): 817-833.
35. Schroder KE, Johnson CJ, Wiebe JS,. Interactive voice response technology applied to sexual behavior self-reports: a comparison of three methods. AIDS Behav 2007; 11 (2): 313-323.
36. Swendeman D, Rotheram-Borus MJ,. Innovation in sexually transmitted disease and HIV prevention: internet and mobile phone delivery vehicles for global diffusion. Curr Opin Psychiatry 2010; 23 (2): 139-144.
37. Andersen BL, Farrar WB, Golden-Kreutz D, et al,. Distress reduction from a psychological intervention contributes to improved health for cancer patients. Brain Behav Immun 2007; 21 (7): 953-961.
38. Antoni MH,. Stress management effects on psychological, endocrinological, and immune functioning in men with HIV infection: empirical support for a psychoneuroimmunological model. Stress 2003; 6 (3): 173-188.